TABLE 1.

Incidence of oesophagitis and pneumonitis observed in selected recent trials

Toxicity: CTCAE	Pneumonitis %		Oesophagitis %
	Any grade	Grade 3–4	Any grade	Grade 3–4
PROCLAIM: standard therapy [96]	10.7	2.6	50.7	20.6
RTOG 0617: 60 Gy [97]	Acute 11.1; late 9.8	Acute 5.5; late 1.2	45.1	6.9
RTOG 0617: 74 Gy [97]	Acute 14.5; late 3.9	Acute 3.4; late 1.1	54.1	17
KCSG-LU05–04: CRT phase [98]	2.4	0	79.3	9.5
CONVERT: LD-SCLC, once daily [99]	Acute 22.4; late 32.6	Acute 1.6; late 2.6	Acute 74; late 18.5	Acute 19.1; late 1.7
CONVERT: LD-SCLC, twice daily [99]	Acute 22; late 31	Acute 1.6; late 2.4	Acute 81.1; late 11.7	Acute 18.5; late 0
PACIFIC: durvalumab [15]	33.9	3.4
PACIFIC: placebo [15]	24.8	2.6
NICOLAS: nivolumab [100]	42.5	10.4	27.5	6.5

CTCAE: Common Terminology Criteria for Adverse Events; CRT: chemoradiotherapy; LD-SCLC: limited disease small cell lung cancer.